metronidazole has been researched along with Furcation Defects in 9 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Furcation Defects: Conditions in which a bifurcation or trifurcation of the molar tooth root becomes denuded as a result of periodontal disease. It may be followed by tooth mobility, temperature sensitivity, pain, and alveolar bone resorption.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metronidazole was applied to the free gingival margins and/or over the exposed membrane at every prophylactic visit (EG)." | 2.71 | Guided tissue regeneration in smokers: effect of aggressive anti-infective therapy in Class II furcation defects. ( Machtei, EE; Oettinger-Barak, O; Peled, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Siqueira, SJ | 1 |
| Ribeiro, FV | 1 |
| Villalpando, KT | 1 |
| Cirano, FR | 1 |
| Pimentel, SP | 1 |
| Machtei, EE | 1 |
| Oettinger-Barak, O | 1 |
| Peled, M | 1 |
| Schacher, B | 1 |
| Baron, F | 1 |
| Ludwig, B | 1 |
| Valesky, E | 1 |
| Noack, B | 1 |
| Eickholz, P | 1 |
| Dowell, P | 1 |
| al-Arrayed, F | 1 |
| Adam, S | 1 |
| Moran, J | 1 |
| Nieminen, A | 1 |
| Asikainen, S | 1 |
| Torkko, H | 1 |
| Kari, K | 1 |
| Uitto, VJ | 1 |
| Saxén, L | 1 |
| Vest, TM | 1 |
| Greenwell, H | 1 |
| Drisko, C | 1 |
| Wittwer, JW | 1 |
| Bichara, J | 1 |
| Yancey, J | 1 |
| Goldsmith, J | 1 |
| Rebitski, G | 1 |
| Worch, KP | 1 |
| Listgarten, MA | 1 |
| Korostoff, JM | 1 |
| Cattabriga, M | 1 |
| Pedrazzoli, V | 1 |
| Wilson, TG | 1 |
| Loesche, WJ | 1 |
| Giordano, JR | 1 |
| Soehren, S | 1 |
| Kaciroti, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures[NCT01116934] | 17 participants (Actual) | Observational | 2006-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions (NCT01116934)
Timeframe: 2006
| Intervention | pg/ml (Median) | ||||
|---|---|---|---|---|---|
| interleukin-1 beta | interleukin-6 | interferon-inducible protein-10 | interferon gamma | interleukin-8 | |
| Healthy Controls | 896.21 | 45734 | 11563 | 3317.4 | 44390 |
| Papillon-Lefèvre Syndrome (PLS) Patients | 1100.00 | 65559 | 12902.5 | 3704.5 | 50520 |
1 review available for metronidazole and Furcation Defects
| Article | Year |
|---|---|
The conservative approach in the treatment of furcation lesions.
Topics: Amputation, Surgical; Anti-Bacterial Agents; Anti-Infective Agents, Local; Dental Scaling; Furcation | 2000 |
5 trials available for metronidazole and Furcation Defects
| Article | Year |
|---|---|
Guided tissue regeneration in smokers: effect of aggressive anti-infective therapy in Class II furcation defects.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Chlorhexidine; Cl | 2003 |
A comparative clinical study: the use of human type I collagen with and without the addition of metronidazole in the GTR method of treatment of periodontal disease.
Topics: Adult; Anti-Infective Agents, Local; Collagen; Dental Plaque Index; Dental Prophylaxis; Dental Scali | 1995 |
Value of some laboratory and clinical measurements in the treatment plan for advanced periodontitis.
Topics: Adult; Aged; Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Anti-Bacterial Agents; Denta | 1996 |
The effect of postsurgical antibiotics and a bioabsorbable membrane on regenerative healing in Class II furcation defects.
Topics: Absorbable Implants; Anti-Bacterial Agents; Anti-Infective Agents; Biocompatible Materials; Bone Reg | 1999 |
The nonsurgical treatment of patients with periodontal disease: results after five years.
Topics: Age Factors; Alveolar Bone Loss; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; D | 2002 |
3 other studies available for metronidazole and Furcation Defects
| Article | Year |
|---|---|
Maintenance periodontal therapy after systemic antibiotic and regenerative therapy of generalized aggressive periodontitis. A case report with 10-year follow-up.
Topics: Adult; Aggressive Periodontitis; Alveolar Bone Loss; Amoxicillin; Anti-Bacterial Agents; Combined Mo | 2015 |
Periodontal therapy in siblings with Papillon-Lefèvre syndrome and tinea capitis: a report of two cases.
Topics: Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Ch | 2006 |
A multidisciplinary approach to the diagnosis and treatment of early-onset periodontitis: a case report.
Topics: Adolescent; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Amoxicillin; Anti-Bacte | 2001 |